◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Nuvalent Inc (NUVL)
来自官方财务报表的收入、利润与现金流历史。
Healthcare · 华尔街（美国） · 最近更新： 2026-08-11
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer.
关键数据
- 市值: $10 billion
- 收入（截至 2025-12-31 财年）: $0M
- 净利润: ($425M)
查看交互式图表与完整报表 →
年度利润表
| 利润表 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|
| 总收入 | $0M | $0M | $0M | $0M | — |
| 营业利润（EBIT） | ($414M) | ($280M) | ($150M) | ($86M) | — |
| 净利 | ($425M) | ($261M) | ($126M) | ($82M) | — |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 NUVL 交互式查看器。 /companies/us/NUVL
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms
TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.